Merck announced ACIP voted to recommend Enflosnia (clesrovimab-cfor) as a treatment option for RSV in infants younger than 8 months of age who are born during or entering their first RSV season.

KYMR has announced that partner Sanofi SNY will not advance the development of lead IRAK4 degrader KT-474. This setback was somewhat offset by KYMR’s announcement of an exclusive option and license ...

Kymera Therapeutics, Inc. has announced an update to its partnership with Sanofi regarding the advancement of a ...

Danish allergy immunotherapy specialist ALK Abello today announced the first market launch of EURneffy (epinephrine) 2mg (the ...

Given that there is no confirmed CDC director and a small newly appointed panel with many members lacking a broad vaccine or immunology knowledge, “there are concerns about the rushed nature of this ...

Kymera Therapeutics, Inc.'s stock rose on KT-621 data, but Sanofi's exit casts doubts. A Gilead Sciences, Inc. deal offers ...

Gilead is betting up to $750 million on Kymera’s anti-CDK2 molecular glue for solid tumors, while Sanofi elected to move ...

Kymera Therapeutics sweetened news of a setback Wednesday, revealing that Sanofi is pulling back from its lead IRAK4 degrader ...

Kymera Therapeutics is celebrating the signing of two partnerships, with Gilead Sciences taking an option on one molecular ...

Kymera signs $750 million CDK2 drug deal with Gilead and earns $20 million from Sanofi as KT-485 advances toward clinical trials in inflammatory diseases.

In a busy day for the US drugmaker, Kymera Therapeutics yesterday announced a licensing deal with Gilead Sciences updated on its collaboration with French pharma major Sanofi.

Kymera on Wednesday said Sanofi won't advance KT-474, which in late 2023 entered Phase 2 studies trials in patients with the inflammatory skin diseases hidradenitis suppurativa and atopic dermatitis.